Screener
ImmunityBio, Inc. IBRX Income Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $51.24M+93.9% | $44.21M+168% | $38.29M+407% | $32.06M+425% | $26.43M+2,424% | ||
| $298K+119% | $238K+310% | $382K— | $177K— | $136K— | ||
| $50.94M+93.8% | $43.97M+167% | $37.9M+402% | $31.88M+422% | $26.29M+2,411% | ||
| 99.4%-0.1pp | 99.5%-0.2pp | 99%-1.0pp | 99.4%-0.6pp | 99.5%-0.5pp | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $112.94M+15.6% | $114M+40.8% | $102.97M+33.8% | $87.69M+1.5% | $97.71M-2.7% | ||
| -$61.7M+13.5% | -$69.79M-8.3% | -$64.68M+6.8% | -$55.63M+30.7% | -$71.29M+28.2% | ||
| -120.4%+149pp | -157.9%+232pp | -169%+750pp | -173.5%+1,141pp | -269.8%+9,218pp | ||
| $17.19M+28.3% | $13.87M+2.5% | $12.3M+6.9% | $12.3M+12.6% | $13.41M+45.3% | ||
| -$168.69M-703% | -$563M-760% | $0— | -$11.68M-112% | -$21.02M+40.4% | ||
| -$230.39M-150% | -$632.79M-387% | -$62.09M-4.9% | -$67.31M+21.5% | -$92.31M+31.4% | ||
| $0-100% | $9K+104% | -$135K— | -$35K— | $269K— | ||
| -$230.38M-149% | -$632.78M-388% | -$61.94M-4.7% | -$67.25M+21.6% | -$92.56M+31.2% | ||
| -449.6%-99.4pp | -1,431.4%-647pp | -161.8%+622pp | -209.8%+1,194pp | -350.3%+12,502pp | ||
| -$0.22-120% | -$0.62-313% | -$0.06+33.3% | -$0.07+50.0% | -$0.10+50.0% | ||
| -$57.29M+15.0% | -$65.41M-7.9% | -$60.82M+6.8% | -$51.68M+31.8% | -$67.41M+29.0% | ||
| -111.8%+143pp | -148%+219pp | -158.9%+705pp | -161.2%+1,080pp | -255.1%+8,811pp | ||
| -$61.7M+13.5% | -$69.79M-8.3% | -$64.68M+6.8% | -$55.63M+30.7% | -$71.29M+28.2% |
FAQ
- What is ImmunityBio, Inc.'s revenue?
- ImmunityBio, Inc. (IBRX) generated $165.8M in revenue over the trailing twelve months, up 192.9% year over year.
- Is ImmunityBio, Inc. profitable?
- ImmunityBio, Inc. is not currently profitable: it reported a net loss of $992.4M over the trailing twelve months, a -598.6% net margin.
- What are ImmunityBio, Inc.'s profit margins?
- Gross margin is 99.3% and operating margin is -151.9%, with a -598.6% net margin.
- What is ImmunityBio, Inc.'s earnings per share?
- ImmunityBio, Inc.'s diluted EPS over the trailing twelve months is $-0.97.
- Where does ImmunityBio, Inc.'s income statement data come from?
- Every line is extracted from ImmunityBio, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
